Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, PE Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-20197R-PE |
| Product Name | Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, PE Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Specificity | This phosphorylation site is homologous in the listed cross reactive species at the specified location. |
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Cow, Chicken, Rabbit |
| Specifications | |
| Conjugation | PE |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human OPRD1 around the phosphorylation site of TP(p-S)DG |
| Modification Site | Ser363 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 4985 |
| Swiss Prot | P41143 |
| Subcellular location | Cell membrane |
| Synonyms | OPRD; Delta-type opioid receptor; D-OR-1; DOR-1; OPRD1 |
| Background | G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | |
| IF(IHC-F) | |
| IF(ICC) | |